Skip to content
Screener

Crinetics Pharmaceuticals CRNX Collaboration and license revenue — Total Revenue

Similar metrics at other companies

PTH
PTHSLicense and collaboration revenues — Total Revenue
$241K
Travere Therapeutics, Inc. logo
TVTXLicense and collaboration revenue — Total Revenue
$2.71M-54.1%
Synopsys logo
SNPSLicense — Total Revenue
$546.25M+7.0%
Guidewire Software logo
GWRELicense — Total Revenue
$56M-2.2%
Spok Holdings logo
SPOKLicense — Total Revenue
$1.36M-48.2%
Alarm.com Holdings logo
ALRMSaaS and license revenue — Total Revenue
$188.78M+11.1%

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$8.9B+233%
Enterprise value$8.84B+231%
P/S492.8×-1,427×

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001658247-26-000040
Line itemThree months ended March 31, 2026Three months ended March 31, 2025
Revenue:
Product revenue, net$10,306
Collaboration and license revenue428361
Total revenue10,734361
Operating expenses:
Cost of product revenue200
Research and development100,08176,240
Selling, general and administrative50,83135,526

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Crinetics Pharmaceuticals's collaboration and license revenue — total revenue?
Crinetics Pharmaceuticals (CRNX) reported collaboration and license revenue — total revenue of $428K in Q1 2026.
How has Crinetics Pharmaceuticals's collaboration and license revenue — total revenue changed year-over-year?
Crinetics Pharmaceuticals's collaboration and license revenue — total revenue increased by 18.6% year-over-year, from $361K to $428K.
What does collaboration and license revenue — total revenue mean?
This metric represents the total revenue recognized from strategic partnerships, research collaborations, and the licensing of intellectual property or drug candidates to third parties. It reflects the company's ability to monetize its research and development pipeline through non-dilutive funding and milestone payments. Fluctuations in this revenue stream typically indicate the timing of clinical development milestones or the execution of new business development agreements.

Ask your AI about Crinetics Pharmaceuticals's collaboration and license revenue — total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude